Filtered By:
Management: Government
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 334 results found since Jan 2013.
UCLA draws record $1.4 billion in research funding
UCLA attracted record support for its wide-ranging research in the 2019 –20 fiscal year, receiving $1.427 billion in research funding.2020 is the third consecutive year that the university has topped its previous best. Research support has grown by 38% since 2015. UCLA now ranks sixth among all universities in total research expenditures.“This is a tribute to the great work being done across disciplines at UCLA,” said Roger Wakimoto, vice chancellor for research. “These funds help bring about major breakthroughs in medical science, advance knowledge in numerous other disciplines, strengthen our teaching, and suppor...
Source: UCLA Newsroom: Health Sciences - October 12, 2020 Category: Universities & Medical Training Source Type: news
Biden ’s Real COVID-19 Challenge Is Restoring a Nation’s Trust in Science
“If the public-health professionals, if Dr. [Anthony] Fauci, if doctors tell us we should take it, I would be first in line. If Donald Trump tells us we should take it, then I’m not taking it.”
That was Vice President-elect Kamala Harris’ response when asked by the moderator of an Oct. 7 debate whether she would get vaccinated against COVID-19. It perfectly captured the politicization of the U.S. response to COVID-19 under the outgoing Trump Administration—and how dangerous that red and blue tinting of the pandemic response has been for the American public. Behaviors like wearing masks and soc...
Source: TIME: Health - November 7, 2020 Category: Consumer Health News Authors: Jamie Ducharme and Alice Park Tags: Uncategorized COVID-19 Source Type: news
The Covid Pandemic: Broadening the Discourse
Thailand’s COVID-19 response an example of resilience and solidarity: a UN Resident Coordinator’s BlogBy Asoka BandarageCOLOMBO, Sri Lanka, Nov 10 2020 (IPS) SARS-CoV-2, the corona virus that causes COVID-19, has been spreading exponentially across the world over the last ten or so months. As of November 6th, according to the Center for Systems Science at Johns Hopkins University, there have been 49,195,581 cases of COVID-19, including 1,241,031 deaths.
More than a third of the global population has been placed on lockdown. The global economy is experiencing the deepest global recession since World War 2 and massive n...
Source: IPS Inter Press Service - Health - November 10, 2020 Category: International Medicine & Public Health Authors: Asoka Bandarage Tags: Featured Global Headlines Health Human Rights Humanitarian Emergencies Peace TerraViva United Nations Source Type: news
Diagnosis of primary immunodeficiencies in Peru
Purpose of review
Primary immunodeficiencies (PIDs) are human inborn errors of immunity, leading to an increased susceptibility to infections, inflammatory manifestations, and malignancy. We estimate around 16 000 individuals with PIDs living in Peru who are still undiagnosed. The purpose of this review is to make a situational analysis of the diagnosis of PIDs in Peru.
Recent findings
There is an evident underdiagnosis of PIDs in Peru. Insufficient awareness and lack of diagnostic tools can be solved partially by expanding the number and expertise of Clinical Immunologists and specialized medical centers. The...
Source: Current Opinion in Pediatrics - November 11, 2020 Category: Pediatrics Tags: ALLERGY, IMMUNOLOGY AND RELATED DISORDERS: Edited by Jordan S. Orange Source Type: research
Moderna ’s COVID-19 Vaccine Is 94.5% Effective. Here’s What That Really Means
It’s wasn’t a typical Sunday morning for Dr. Stephen Hoge, president of the biotech company Moderna, and Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. They were at their respective homes in Massachusetts and Washington, D.C., waiting to to be let into a Zoom call to hear the results of the very first COVID-19 vaccine that was tested in people.
The hosts were members of the independent Data Safety Monitoring Board (DSMB) that is reviewing data involving all the COVID-19 vaccine candidates supported by the U.S. government’s Operation Warp Speed program, and Hoge a...
Source: TIME: Health - November 17, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
COVID-19 Vaccines Are Coming. Here ’s What to Expect
Vaccines normally take decades to develop and test, but two COVID-19 shots, from Moderna and Pfizer (in partnership with BioNTech), have gone from nonexistent to about 95% effectiveness in 10 months. Public-health officials and governments now have the dual challenge of convincing the public that the vaccines are both safe and scientifically sound, as well as figuring out how to distribute billions of doses. Here’s what we know so far about how that’s going.
When can I get vaccinated?
That depends.
Manufacturers have already begun producing vaccines, betting that they will be effective, so they can be ready to ...
Source: TIME: Science - November 19, 2020 Category: Science Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Yes, We Have COVID-19 Vaccines That Are 95% Effective. But That Doesn ’t Mean the End of the Pandemic is Near
It’s a rare glimmer of hope in a brutal and battering pandemic year: in November, both Moderna and Pfizer reported that their much-anticipated COVID-19 vaccines are 95% effective in protecting people against getting sick with the disease.
Scientists were encouraged (and even surprised by the magnitude of the protection), public health officials finally saw what could be the beginning of the end of the pandemic, and families everywhere began fantasizing about a return to normalcy where gathering around the table to celebrate the holidays are a given and not a matter of public health concern.
But the same public health...
Source: TIME: Health - November 20, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Moderna Requests Emergency FDA Authorization for COVID-19 Vaccine
Moderna is requesting emergency authorization from the Food and Drug Administration (FDA) for its COVID-19 vaccine on Monday — a development the company’s president tells TIME is an “incredible milestone.”
The filing for the company’s mRNA-based vaccine is the first step toward getting the shot into hospitals, pharmacies and health centers. The Massachusetts-based biotech is the second company, following Pfizer, to request authorization for a COVID-19 vaccine.
Unlike Pfizer’s shot, which is also based on mRNA, Moderna’s vaccine does not need to be stored at ultra cold temperatures ...
Source: TIME: Health - November 30, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 News overnight Source Type: news
Fueled by a History of Mistreatment, Black Americans Distrust the New COVID-19 Vaccines
When a COVID-19 vaccine becomes widely available to Americans, Brianna Clarke says she won’t be taking it.
“I don’t trust the vaccine,” the 22-year-old says. “I think it’s too soon to have a vaccine.” Clarke, who lives in Willingboro, N.J., is among a significant number of Black Americans who are skeptical of the healthcare industry in general and, critically, the COVID-19 vaccines recently developed by pharmaceutical companies Pfizer-BioNTech and Moderna, more specifically.
Over the past couple of weeks, the U.S. has averaged in the neighborhood of 200,000 new COVID-19 cases per d...
Source: TIME: Health - December 28, 2020 Category: Consumer Health News Authors: Dezimey Kum Tags: Uncategorized COVID-19 Source Type: news
mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!”
I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed.
This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news
Fauci on What Working for Trump Was Really Like
From denialism to death threats, Dr. Anthony S. Fauci describes a fraught year as an adviser to President Donald J. Trump on the Covid-19 pandemic.
Source: NYT - January 25, 2021 Category: American Health Authors: Donald G. McNeil Jr. Tags: Fauci, Anthony S Trump, Donald J Coronavirus (2019-nCoV) National Institute of Allergy and Infectious Diseases Threats and Threatening Messages Rumors and Misinformation United States Politics and Government your-feed-health your-feed-scie Source Type: news
Johnson & Johnson ’s COVID-19 Vaccine Results Are Better Than They May Sound
Johnson & Johnson’s Janssen Pharmaceutical Companies announced on Jan. 29 that its one-shot COVID-19 vaccine is 66% effective in protecting against disease, but 85% effective against preventing severe disease—results that could make it especially valuable in the effort to vaccinate parts of the world with weak health care systems.
By comparison, the vaccines already authorized in the U.S.—one from Moderna and one from Pfizer-BioNTech—each require two doses, spaced three to four weeks apart. Janssen’s vaccine can also be stored in normal refrigerators, unlike Moderna’s and Pfizer-BioN...
Source: TIME: Health - January 29, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
